Research Education

研究教育

基本信息

批准号：
10762294
负责人：
Maurizio Pellecchia
金额：
$ 13.07万
依托单位：
UNIVERSITY OF CALIFORNIA RIVERSIDE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-22 至 2028-08-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10762294
关键词：
African American American Antineoplastic Agents Applications Grants Award Basic Science Bioinformatics Biology California Catchment Area City of Hope Comprehensive Cancer Center Clinical Clinical Research Clinical Trials Communities Comprehensive Cancer Center Conduct Clinical Trials Core Facility Data Development Disparity Drug Design Drug Targeting Education Education and Outreach Educational Activities Educational Curriculum Engineering Equity Ethics European Faculty Funding Goals Grant Health Disparities Research Hispanic Americans Hispanic-serving Institution Interview Investments Joints Laboratories Latino Master of Science Medical Students Mentorship Methods NCI Center for Cancer Research Participant Pathway interactions Patients Pharmaceutical Preparations Phase Physicians Postbaccalaureate Postdoctoral Fellow Precision Medicine Initiative Reporting Research Research Infrastructure Research Personnel Research Training Resources Rotation Scientist Site Societies Structure Students System Testing Training Training Programs Translating Translations United States United States Food and Drug Administration United States National Institutes of Health Universities Work Writing anticancer research cancer health disparity career chimeric antigen receptor T cells commercialization curriculum development disparity elimination diversity and inclusion drug development drug discovery drug repurposing education research ethnic diversity experience first-in-human graduate school graduate student health disparity innovation long-standing disparities manufacturing facility medical schools minority communities nanotherapy news next generation novel therapeutics precision medicine programs research and development screening social determinants stem cell therapy student training success summer research summer student targeted agent undergraduate student

项目摘要

Cancer drugs in the United States are almost exclusively developed by, tested in, and optimized for European- Americans. Disparities in U.S. drug development are the result of long-standing inequalities that occur throughout the entire drug discovery pipeline. Only a small number of basic, translational, and clinical scientists are Latino/Hispanic-American or African-American. Less than 2-5% of trial participants are Latino/Hispanic- American or African-American. Yet, in spite of a lack of data, new drugs are approved by the U.S. Food and Drug Administration (FDA), and subsequently prescribed for Latino/Hispanic-American or African-American patients, without sufficient testing. It is unacceptable, especially in this era of the Precision Medicine Initiative (PMI), that our drugs are currently developed by, and optimized for, only an exclusive segment of our citizens. We seek to shift this paradigm by strengthening the existing partnership between University of California at Riverside (UCR) and City of Hope Comprehensive Cancer Center (CoHCCC). The goal of our U54 Research Education Core is for UCR and CoHCCC to collaboratively develop the research infrastructure and training programs necessary to develop the next generation of therapeutics researchers that reflect the ethnic diversity of Inland Southern California. To this end, the UCR – CoHCCC Research Education Core will integrate research experiences, curriculum development, and outreach education activities that focus on 1) opportunities in drug discovery, 2) resources to translate basic science discovery to drive drug development, and 3) training in the biology, ethics, and social determinants of disparities. Aim 1 will develop research pathways to increase capacity in drug development and clinical trials. Aim 2 will develop courses to introduce both UCR and CoH students and faculty to methods and innovation in drug development and the health science of disparities. (students, PDF, early stage investigators (ESI), established faculty). Aim 3 will 1) expose students, PDF, ESI to career opportunities in drug development and clinical trials and 2) provide training and capacity building.

美国的癌症药物几乎由针对欧洲进行，测试和优化。美国人。美国药物开发的差异是整个过程中长期存在不平等的结果整个药物发现管道。只有少数基本，翻译和临床科学家是拉丁裔/西班牙裔美国人或非裔美国人。不到2-5％的审判参与者是拉丁裔/西班牙裔 - 美国或非裔美国人。然而，尽管缺乏数据，但新药得到了美国食品的批准，药物管理局（FDA），随后针对拉丁裔/西班牙裔美国人或非裔美国人的规定患者，没有足够的测试。这是不可接受的，尤其是在精确医学倡议的时代（PMI），我们的药物目前是由我们公民的独家部分开发和优化的。我们寻求通过加强加利福尼亚大学AT之间的现有合作伙伴关系来改变这一范式 Riverside（UCR）和Hope City of Ampocial癌症中心（COHCCC）。我们U54研究的目标教育核心是UCR和CoHCCC协作开发研究基础设施和培训的发展下一代治疗学研究人员所必需的计划，以反映种族多样性南加州内陆。为此，UCR - COHCCC研究教育核心将整合研究重点关注的经验，课程发展和外展教育活动1）发现，2）翻译基础科学发现以推动药物开发的资源，3）培训生物学，伦理和社会决定者的差异。 AIM 1将开发研究途径以增加容量在药物开发和临床试验中。 AIM 2将开发课程，以介绍UCR和COH学生以及对药物开发和分配健康科学的方法和创新的教师。（学生，PDF，早期研究人员（ESI），已建立的教师）。 AIM 3将1）暴露学生，PDF，ESI到职业药物开发和临床试验的机会以及2）提供培训和能力建设。